{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang H"],"funding":["Xijing Hospital Medical Personnel Training Propel Project","National Natural Science Fund"],"pagination":["933-940"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12505089"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(19)"],"pubmed_abstract":["<h4>Background</h4>Patients with drug-refractory non-obstructive hypertrophic cardiomyopathy (NOHCM) lack effective invasive treatment options. This study aimed to evaluate the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA, Liwen procedure) in patients with NOHCM and severe septal hypertrophy (≥28 mm).<h4>Method</h4>This single-arm, open-label, prospective study enrolled 20 adult patients with drug-refractory NOHCM between June 2017 and June 2023. Patients underwent PIMSRA and were followed for a median of 15 months. Outcomes included changes in septal thickness, quality of life (Kansas City Cardiomyopathy Questionnaire-12, KCCQ-12) and myocardial function.<h4>Results</h4>No major adverse clinical events occurred within 30 days after the pr"],"journal":["Heart (British Cardiac Society)"],"pubmed_title":["Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy."],"pmcid":["PMC12505089"],"funding_grant_id":["XJZT24LY01","82230065"],"pubmed_authors":["Yao L","Chang L","Li J","Liu L","Wang B","Hsi DH","Ta S","Wang H","Shan B","Wang J","Lei C","Li W","Ou X","Jiao Y"],"additional_accession":[]},"is_claimable":false,"name":"Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.","description":"<h4>Background</h4>Patients with drug-refractory non-obstructive hypertrophic cardiomyopathy (NOHCM) lack effective invasive treatment options. This study aimed to evaluate the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA, Liwen procedure) in patients with NOHCM and severe septal hypertrophy (≥28 mm).<h4>Method</h4>This single-arm, open-label, prospective study enrolled 20 adult patients with drug-refractory NOHCM between June 2017 and June 2023. Patients underwent PIMSRA and were followed for a median of 15 months. Outcomes included changes in septal thickness, quality of life (Kansas City Cardiomyopathy Questionnaire-12, KCCQ-12) and myocardial function.<h4>Results</h4>No major adverse clinical events occurred within 30 days after the pr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-04T05:59:38.993Z","creation":"2026-05-06T03:07:53.707Z"},"accession":"S-EPMC12505089","cross_references":{"pubmed":["40054888"],"doi":["10.1136/heartjnl-2024-325334"]}}